The European Medicines Agency has validated its Type II Variation Marketing Authorization Applications for both Opdivo (nivolumab) in combination with Yervoy (ipilimumab) and Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatments for adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.
The European Commission has granted orphan drug designation to sabatolimab (MBG453) for the treatment of myelodysplastic syndromes, based on clinical data showing a high rate of responses in patients with high-risk MDS who were treated with sabatolimab in combination with hypomethylating agents.
Foundation Medicine Inc. is partnering with Epic to integrate its comprehensive genomic profiling and other testing services with Epic’s electronic medical record system.
Werewolf Therapeutics Inc. has entered into a clinical trial collaboration and supply agreement with Merck to evaluate WTX-124, a systemically-delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE product candidate, in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy.
The National Cancer Institute approved the following clinical research studies last month.
Two decades ago, when Fred Hutch, the University of Washington and Seattle Children’s formed a consortium, they created the Seattle Cancer Care Alliance to serve as a hub of clinical operations.
Twenty years ago, when Fred Hutch, the University of Washington and Seattle Children’s created a united cancer program in Seattle, they relied on an entity called Seattle Cancer Care Alliance to deliver the consortium’s clinical services.
A House appropriations subcommittee voted to increase NIH’s FY2022 budget by $6.5 billion—to $46.43 billion—which falls $2.5 billion short of President Joe Biden’s request for NIH.
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center has earned renewal of its NCI designation as a Comprehensive Cancer Center for another five years.
Olufunmilayo I. Olopade will receive the William L. McGuire Memorial Lecture Award at the 2021 San Antonio Breast Cancer Symposium Dec. 7-10, 2021.
